Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
IMNN Stock Forecast 2025-2026
$0.88
Current Price
$12.71M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to IMNN Price Targets
+3,195.5%
To High Target of $29.00
+1,263.6%
To Median Target of $12.00
+468.2%
To Low Target of $5.00
IMNN Price Momentum
-1.1%
1 Week Change
-19.3%
1 Month Change
-38.9%
1 Year Change
-7.4%
Year-to-Date Change
-75.9%
From 52W High of $3.65
+37.5%
From 52W Low of $0.64
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Imunon (IMNN) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on IMNN and similar high-potential opportunities.
Latest IMNN Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, IMNN has a bullish consensus with a median price target of $12.00 (ranging from $5.00 to $29.00). Currently trading at $0.88, the median forecast implies a 1,263.6% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jason Kolbert at D. Boral Capital, projecting a 3,195.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IMNN Analyst Ratings
4
Buy
0
Hold
0
Sell
IMNN Price Target Range
Low
$5.00
Average
$12.00
High
$29.00
Current: $0.88
Latest IMNN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IMNN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 26, 2025 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $14.00 |
| Mar 24, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $29.00 |
| Feb 27, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $29.00 |
| Feb 19, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $29.00 |
| Jan 24, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $29.00 |
| Dec 19, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $29.00 |
| Dec 19, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $12.00 |
| Dec 11, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $12.00 |
| Dec 10, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $29.00 |
| Nov 25, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $29.00 |
| Nov 11, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $12.00 |
| Nov 7, 2024 | EF Hutton | Jason Kolbert | Buy | Maintains | $29.00 |
| Oct 31, 2024 | EF Hutton | Jason Kolbert | Buy | Maintains | $29.00 |
| Sep 23, 2024 | EF Hutton | Jason Kolbert | Buy | Initiates | $29.00 |
| Aug 15, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $14.00 |
| Aug 5, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $14.00 |
| May 14, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $12.00 |
| Apr 1, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $13.00 |
| Mar 13, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $12.00 |
| Sep 15, 2023 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $12.00 |
Imunon Inc. (IMNN) Competitors
The following stocks are similar to Imunon based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Imunon Inc. (IMNN) Financial Data
Imunon Inc. has a market capitalization of $12.71M with a P/E ratio of -0.5x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -211.2%.
Valuation Metrics
Market Cap
$12.71M
Enterprise Value
$8.10M
P/E Ratio
-0.5x
PEG Ratio
-0.8x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+45.7%
Current Ratio
1.7x
Debt/Equity
26.8x
ROE
-211.2%
ROA
-75.6%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Imunon Inc. (IMNN) Business Model
About Imunon Inc.
What They Do
Develops innovative biopharmaceutical treatments for oncology.
Business Model
The company focuses on research and development of proprietary technologies to improve drug delivery and effectiveness, particularly in oncology. It generates revenue through the advancement of its innovative treatments and potential partnerships or licensing agreements in the biopharmaceutical sector.
Additional Information
Imunon Inc. prioritizes unmet medical needs and aims to enhance the efficacy of traditional cancer treatments through its proprietary ThermoDox® technology. Its commitment to innovation positions it as a key player in the biopharmaceutical industry, addressing critical challenges in cancer treatment and improving patient outcomes.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
25
CEO
Dr. Stacy R. Lindborg Ph.D.
Country
United States
IPO Year
1999
Website
imunon.comImunon Inc. (IMNN) Latest News & Analysis
Latest News
IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting
7 days ago
Quick Summary
The OVATION 2 Study will present promising survival data for a treatment targeting newly diagnosed advanced ovarian cancer.
Why It Matters
Positive survival data from the OVATION 2 Study could indicate potential for successful treatment options, impacting stock prices and investor sentiment in related biotech companies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer
1 month ago
Quick Summary
A Phase 2 trial has shown that a new immunotherapy is the first to provide a significant overall survival benefit for patients with advanced ovarian cancer.
Why It Matters
This breakthrough immunotherapy's success could lead to increased market share, higher revenues for the company, and potential stock price growth, attracting investor interest in biotech.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Imunon, Inc. (IMNN) Q4 2024 Earnings Call Transcript
2 months ago
Quick Summary
Imunon, Inc. (NASDAQ:IMNN) will hold its Q4 2024 results conference call on February 26, 2025, at 11:00 AM ET, featuring key executives and financial analysts.
Why It Matters
Imunon, Inc.'s upcoming Q4 2024 results call is a key event for assessing financial performance and strategic direction, impacting investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
IMNN-001 is the first immunotherapy to demonstrate a significant overall survival benefit in patients with advanced ovarian cancer.
Why It Matters
IMNN-001's success in advanced ovarian cancer may boost the company's stock, indicating potential market dominance and increased revenue from new therapies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19
2 months ago
Quick Summary
IMNN-101 Proof-of-Concept study shows lasting immunogenicity in participants, supporting the efficacy of PlaCCine® technology.
Why It Matters
Positive results from the IMNN-101 study indicate strong potential for PlaCCine® technology, potentially boosting investor confidence and driving stock valuation in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025
2 months ago
Quick Summary
IMUNON, Inc. (NASDAQ: IMNN) will report its 2024 financial results on February 27, 2025, before market opening, followed by a conference call at 11:00 a.m. ET for updates.
Why It Matters
The upcoming financial results and conference call could signal IMUNON's performance and outlook, influencing stock price and investor sentiment regarding its immunotherapy development.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About IMNN Stock
What is Imunon Inc.'s (IMNN) stock forecast for 2025?
Based on our analysis of 4 Wall Street analysts, Imunon Inc. (IMNN) has a median price target of $12.00. The highest price target is $29.00 and the lowest is $5.00.
Is IMNN stock a good investment in 2025?
According to current analyst ratings, IMNN has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.88. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IMNN stock?
Wall Street analysts predict IMNN stock could reach $12.00 in the next 12 months. This represents a 1,263.6% increase from the current price of $0.88. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Imunon Inc.'s business model?
The company focuses on research and development of proprietary technologies to improve drug delivery and effectiveness, particularly in oncology. It generates revenue through the advancement of its innovative treatments and potential partnerships or licensing agreements in the biopharmaceutical sector.
What is the highest forecasted price for IMNN Imunon Inc.?
The highest price target for IMNN is $29.00 from Jason Kolbert at D. Boral Capital, which represents a 3,195.5% increase from the current price of $0.88.
What is the lowest forecasted price for IMNN Imunon Inc.?
The lowest price target for IMNN is $5.00 from at , which represents a 468.2% increase from the current price of $0.88.
What is the overall IMNN consensus from analysts for Imunon Inc.?
The overall analyst consensus for IMNN is bullish. Out of 4 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $12.00.
How accurate are IMNN stock price projections?
Stock price projections, including those for Imunon Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 28, 2025 3:35 PM UTC